Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

4 top dna testing stocks to buy in 2024

Ready to invest in the genetic testing industry? Learn how to invest in dna testing stocks in just a few steps.

DNA testing is getting more popular, and interest in investing in genetics is trending up as well. While a lot of the most popular names in home DNA test kits, like 23andme and Ancestry, aren't yet publicly traded, there are still plenty of companies that let you invest on the trend. There are also new IPOs in this field, with via a merger with VG Acquisition (VGAC).

The best genetic testing stocks depend on your portfolio and investment goals — while volatility can be ideal for day traders, long-term investors will want to look to stocks with steadier gains over time.

The top genetic testing stocks included on this page all trade on the S&P 500, have an analyst recommendation of "Buy" or better and are sorted by year-to-date performance.

  1. Natera (NTRA)
  2. Genetic Technologies (GENE)
  3. VG Acquisition (VGAC)
  4. Sangamo Therapeutics (SGMO)

Our top broker picks

Best for beginners

Go to site
Get up to $1,000 in stock
  • No-cost financial planning and automated investing
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Best for mobile experience

Go to site
3% IRA match with Robinhood Gold
  • Earn 5% interest on uninvested cash with Gold
  • Get up to $50,000 in instant deposits with Gold
  • Easy, user-friendly trading

How to invest in dna testing stocks

  1. Choose an online stock trading platform. Choose from our Top Picks above, use our comparison table below or jump straight to the best stock trading apps of 2024.
  2. Sign up for an account. Provide your personal information and sign up.
  3. Set up a funding method to pay for the transaction. Deposit funds into your account by linking your banking information.
  4. Choose the stocks you want to buy. Search for the stock by name or ticker symbol like NTRA or GENE.
  5. Place your order. Buy the stock. It's that simple.

Take a deeper dive into dna testing stocks

If you're interested in investing in the genetic testing industry, take a closer look at what companies in this industry do and how the stocks have historically performed. Keep in mind that positive past performance doesn't guarantee that a stock will continue to rise in the future.

1. Natera (NTRA)

Natera, Inc. , a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Natera stock opened the day at $107.23 after a previous close of $107.20. The latest price was $107.11 (25-minute delay). Natera is listed on the NASDAQ, has a trailing 12-month revenue of around USD1.2 billion and employs 3,282 staff.

  • Market capitalization: $13,532,890,112
  • PEG ratio: 0

Back to top


2. Genetic Technologies (GENE)

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.

Genetic Technologies stock opened the day at $1.66 after a previous close of $1.65. The latest price was $1.70 (25-minute delay). Genetic Technologies is listed on the NASDAQ, has a trailing 12-month revenue of around USD$10.2 million and employs 60 staff.

  • Market capitalization: $6,020,979
  • PEG ratio: 0

Back to top


3. VG Acquisition (VGAC)

VG Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.

VG Acquisition is listed on the NYSE.

  • Market capitalization: $698,619,968

Back to top


4. Sangamo Therapeutics (SGMO)

Sangamo Therapeutics, Inc. , a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

Sangamo Therapeutics stock opened the day at $0.45 after a previous close of $0.44. The latest price was $0.45 (25-minute delay). Sangamo Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$18.8 million and employs 405 staff.

  • Market capitalization: $103,775,752
  • PEG ratio: 0

Back to top

Bottom line

While it’s possible to turn a profit investing in dna testing stocks, keep in mind that — like any investment — dna testing stocks are not immune to risk. These stocks are subject to fluctuating conditions — both in the market and in the genetic testing industry, so carefully vet your picks before you invest. And if you’re new to investing, or if it’s been awhile since you’ve taken a critical look at your investing accounts, compare brokers to make sure you’re getting the best features in your trading account.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

More guides on Finder

Ask a Question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site